Please login to the form below

Not currently logged in

Merck to launch Tredaptive internationally

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009.

Tredaptive (also known as Cordaptive) is a therapy for patients with mixed dyslipidemia and primary hypercholesterolemia. It has been licensed in the EU for use in combination with statins or as a monotherapy when statins are inappropriate.

It is approved for use in 39 countries outside of the US. The FDA refused to approve the drug for use in the US until more supporting evidence was available.

"Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care," said Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular, Merck Research Laboratories.

19th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...